BioSpace News Archive

The study on the mobile CT scanners market presents a detailed assessment of key growth dynamics, major technological advances, share and size of various segments, prominent regions, and top regional markets.

The surge in medical smart glasses market is anticipated to witness prominent growth during the forecast period set between 2020 and 2030.

Electrophysiology studies are frequently used in indications of abnormal heart rhythms, to understand the underlying causes and help clinicians decide the most useful treatments.

The growing demand for endoscopic procedures is likely to play an important role in the growth of the global endoscopic submucosal dissection market over the period of assessment, from 2020 to 2030.

The fatality rates associated with the occurrence cystic fibrosis has intensified the concerns of the medical industry.

The demand within the global complement 3 glomerulopathy treatment market is poised to touch new heights in the times to follow.

The allergic rhinitis treatment devices refer to those devices that are utilized for the purpose of treating allergic rhinitis.

Polyphor AG announced that the clinical trial independent Data Safety Monitoring Board has completed the third, pre-specified interim analysis, of safety outcomes based on a data cut off of 401 randomized patients in the Phase III pivotal study with balixafortide in HER2 negative, locally recurrent or metastatic breast cancer patients.

Masimo announced the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Kumagai and colleagues at Iwate Medical University Hospital in Yahaba-cho, Japan investigated whether Masimo ORi™, Oxygen Reserve Index, could be used to limit the extent of postoperative hyperoxia.1 The researchers concluded that ORi helped “suppress hyperoxia, preventing hypoxia.”.

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 fusions.